ShareCompartir
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: [email protected]. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Errata: Vol. 60, No. 48
In the report, "Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection," errors occurred. On page 1653, in Box 2, the fourth bullet point should begin, "Baseline hepatic chemistry blood tests (at least alanine aminotransferase [ALT]) for patients with specific conditions:"
On page 1651, in the multination treatment trial described in the second full paragraph, the treating physicians had the option of prescribing oral pyridoxine 50 mg for administration with each dose of both the weekly isoniazid-rifapentine and the daily isoniazid-only regimens. Weekly pyridoxine 50 mg for prophylaxis of isoniazid-associated peripheral neuropathy should be considered with the isoniazid-rifapentine regimen, especially for persons who are malnourished or predisposed by other illnesses to peripheral neuropathy.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All MMWR HTML versions of articles are electronic conversions from typeset documents.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S.
Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
[email protected].
